AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Sep 13, 2018

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in adult patients with moderate to severe plaque psoriasis. Across all three trials, patients reported significant improvements in health-related quality of life, mental health and work productivity measures when treated with risankizumab.1,2 Data from these studies will be presented at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris. Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

Sep 11, 2018

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label

NORTH CHICAGO, Ill., Sept. 11, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA® (venetoclax tablets) in combination with rituximab to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.

Sep 07, 2018

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 7, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share.

Sep 05, 2018

Public Voting is Open for the 2018 AbbVie CF Scholarship Thriving Student Awards, Given to Two Exceptional Students Living with Cystic Fibrosis

NORTH CHICAGO, Ill., Sept. 5, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced its annual call for the public to vote for students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system, as part of its 2018 Thriving Student Scholarship. Scholarships totaling $25,000 each – the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship – will be awarded to two deserving students.

Sep 04, 2018

AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress

NORTH CHICAGO, Ill., Sept. 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-16, in Paris.

Aug 28, 2018

AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., Aug. 28, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018. Bill Chase, executive vice president and chief financial officer, will present at 10:40 a.m. Central time.

Aug 27, 2018

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer

NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) plus rituximab (RITUXAN®) for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL). With this approval, the IMBRUVICA prescribing information now includes combination use with rituximab, representing the first and only chemotherapy-free combination treatment specifically indicated for the disease. IMBRUVICA was first approved as a single agent therapy for WM in January 2015. IMBRUVICA is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

Aug 22, 2018

AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

NORTH CHICAGO, Ill., Aug. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed at month 12 that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 87.9 percent of women with uterine fibroids achieving clinical response.

Aug 20, 2018

AbbVie Announces $100 Million Donation to Ronald McDonald House Charities to Support Hospitalized Children and Their Families

NORTH CHICAGO, Ill., Aug. 20, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to Ronald McDonald House Charities (RMHC). This donation, the largest single gift in RMHC's history, will provide housing and family-centered services for pediatric patients and their families during hospital treatment across the United States.

Jul 27, 2018

AbbVie Reports Second-Quarter 2018 Financial Results

NORTH CHICAGO, Ill., July 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the second quarter ended June 30, 2018.